Rani Therapeutics Holdings, Inc. Income Statement
RANI|4 years of annual SEC 10-K data (FY2021-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 4 fiscal years. All figures from audited SEC 10-K filings.
Rani Therapeutics Holdings, Inc. reported $1M in revenue and $30M in net loss for FY2025. Revenue has grown at a 22.1% compound annual rate over the past 4 years.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -1.77 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $1.0M | $0 | $2.7M | $462.0K |
| SG&A Expense | $23.9M | $26.5M | $27.8M | $5.0M |
| R&D Expense | $26.7M | $39.6M | $26.5M | $12.0M |
| Operating Income | -$53.3M | -$66.1M | -$51.6M | -$16.5M |
| Interest Expense | $5.0M | $5.1M | $466.0K | $124.0K |
| Income Tax | $0 | $0 | $41.0K | $35.0K |
| Net Income | -$30.0M | -$34.0M | -$8.3M | -$8.3M |
| EPS (Basic) | -$1.05 | -$1.33 | -$0.43 | - |
| EPS (Diluted) | -$1.05 | -$1.33 | -$0.43 | -$0.43 |
| Shares Outstanding | 28.5K | 25.5K | 19.5K | 19.5M |
| Operating Margin | -5186.2% | - | -1899.1% | -3580.9% |
| Profit Margin | -2920.0% | - | -306.6% | -1803.3% |